Anthony C. Hooper

CIK: 0001277244

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)6 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

ONC

BeOne Medicines Ltd.

Director

MNKD

MANNKIND CORP

Director

Discretionary Trading P&L

Holdings

Transaction History (6 total)

ONC
BeOne Medicines Ltd.
Jun 11, 2026
Award(A)
Direct
19K shares-
MNKD
MANNKIND CORP
May 20, 2026
Award(A)
Restricted Stock Unit
Direct
82.8K shares-
MNKD
MANNKIND CORP
May 20, 2026
Award(A)
Restricted Stock Unit
Direct
16.6K shares-
MNKD
MANNKIND CORP
Mar 1, 2026
Award(A)
Direct
35K shares at avg. $3.27$114K
BGNE
BeiGene, Ltd.
May 21, 2025
Award(A)
Direct
11K shares-
MNKD
MANNKIND CORP
May 14, 2025
Award(A)
Direct
25K shares at avg. $4.56$114K

		Type	Shares	Price		Ownership
Jun 11, 2026	ONC BeOne Medicines Ltd.	Award(A)	18,980	-	$0	Direct
May 20, 2026	MNKD MANNKIND CORP	Award(A) Restricted Stock Unit	82,781	-	-	Direct
May 20, 2026	MNKD MANNKIND CORP	Award(A) Restricted Stock Unit	16,556	-	-	Direct
Mar 1, 2026	MNKD MANNKIND CORP	Award(A)	35,000	$3.27	$114,450	Direct
May 21, 2025	BGNE BeiGene, Ltd.	Award(A)	10,985	-	-	Direct
May 14, 2025	MNKD MANNKIND CORP	Award(A)	25,000	$4.56	$114,000	Direct

1-6 of 6 transactions

About HOOPER ANTHONY C

HOOPER ANTHONY C (SEC CIK 0001277244) files insider reports with the SEC as Director of BeOne Medicines Ltd. (ONC) and Director of MANNKIND CORP (MNKD).

Signal8 holds 5 ownership filings by HOOPER ANTHONY C, all Form 4s, filed between May 16, 2025 and Jun 15, 2026. Those filings report 6 transactions, from May 14, 2025 to Jun 11, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on HOOPER ANTHONY C's filings is in BASEL.

Recent filings by HOOPER ANTHONY C

Jun 11, 2026: Grant or award of ONC shares (Form 4, code A).
May 20, 2026: Grants or awards of MNKD derivative securities (2 lines, Form 4, code A).
Mar 1, 2026: Grant or award of MNKD shares (Form 4, code A).
May 21, 2025: Grant or award of BGNE shares (Form 4, code A).
May 14, 2025: Grant or award of MNKD shares (Form 4, code A).

Other insiders filing for BeOne Medicines Ltd. (ONC)

Wang Xiaodong, Director
Lee Chan Henry, SVP, General Counsel
Ball Titus B., Principal Accounting Officer
Wu Xiaobin, President and COO
OYLER JOHN, Chief Executive Officer
Rosenberg Aaron, Chief Financial Officer

How to read Form 4 transaction codes